Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

New research highlights how the brain’s own chemistry can suppress pain, explaining why severely injured individuals, like WWII soldiers, sometimes feel little discomfort.

What should investors who are experiencing Nasdaq market whiplash do now? I think buying three Nasdaq stocks hand over fist and holding them for decades is a smart move.

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...

Journavx, a non-opioid pain signal inhibitor ... driven by recent personnel changes at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), we believe ...

Dextenza is not recommended for treating ocular itching with allergic conjunctivitis in children who require sedation for the insertion procedure. The Food and Drug Administration (FDA) has ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual ...